ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo

ClinicalTrials.gov ID: NCT04927975

Public ClinicalTrials.gov record NCT04927975. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 4:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Non-Segmental Vitiligo

Study identification

NCT ID
NCT04927975
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AbbVie
Industry
Enrollment
185 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Upadacitinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 29, 2021
Primary completion
Jan 12, 2023
Completion
Aug 28, 2023
Last update posted
Oct 7, 2024

2021 – 2023

United States locations

U.S. sites
20
U.S. states
12
U.S. cities
19
Facility City State ZIP Site status
University of California Irvine /ID# 229390 Irvine California 92697-1385
Stanford University /ID# 228000 Redwood City California 94063
Clearlyderm Dermatology /ID# 227993 Boca Raton Florida 33428
New Horizon Research Center /ID# 229403 Miami Florida 33165-3372
Park Avenue Dermatology, PA /ID# 229400 Orange Park Florida 32073
ForCare Clinical Research /ID# 228010 Tampa Florida 33613-1244
Dawes Fretzin, LLC /ID# 227996 Indianapolis Indiana 46256
Tufts Medical Center /ID# 228087 Boston Massachusetts 02111-1552
Duplicate_UMass Chan Medical School /ID# 228066 Worcester Massachusetts 01655
Duplicate_Michigan Center for Research Company /ID# 228054 Clarkston Michigan 48346
Hamzavi Dermatology /ID# 228056 Fort Gratiot Michigan 48059
Remington-Davis Clinical Research /ID# 229401 Columbus Ohio 43215
Essential Medical Research, LLC /ID# 228074 Tulsa Oklahoma 74137-2842
Oregon Dermatology and Research Center /ID# 228007 Portland Oregon 97210
Oregon Medical Research Center /ID# 228073 Portland Oregon 97223
Duplicate_Medical University of South Carolina /ID# 228067 Charleston South Carolina 29425
International Clinical Research - Tennessee LLC /ID# 228059 Murfreesboro Tennessee 37130-2450
Bellaire Dermatology Associates /ID# 228004 Bellaire Texas 77401
University of Texas Health Science Center at Houston /ID# 229399 Houston Texas 77030-1501
Virginia Clinical Research, Inc. /ID# 228050 Norfolk Virginia 23502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04927975, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 7, 2024 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04927975 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →